

## Product datasheet for TL313669V

#### OriGene Technologies, Inc.

9620 Medical Center Drive, Ste 200 Rockville, MD 20850, US Phone: +1-888-267-4436 https://www.origene.com techsupport@origene.com EU: info-de@origene.com CN: techsupport@origene.cn

### CTLA4 Human shRNA Lentiviral Particle (Locus ID 1493)

#### **Product data:**

**Product Type:** shRNA Lentiviral Particles

**Product Name:** CTLA4 Human shRNA Lentiviral Particle (Locus ID 1493)

**Locus ID:** 1493

Synonyms: ALPS5; CD; CD152; CELIAC3; CTLA-4; GRD4; GSE; IDDM12

**Vector:** pGFP-C-shLenti (TR30023)

Format: Lentiviral particles

Components: CTLA4 - Human shRNA lentiviral particles (4 unique 29mer target-specific shRNA, 1 scramble

control), 0.5 ml each, >10^7 TU/ml.

RefSeq: NM 001037631, NM 005214, NM 005214.1, NM 005214.2, NM 005214.3, NM 005214.4,

NM 001037631.1, NM 001037631.2, BC069566, BC069566.1, BC070162, BC074842, BC074893,

NM 005214.5, NM 001037631.3

UniProt ID: P16410

**Summary:** This gene is a member of the immunoglobulin superfamily and encodes a protein which

transmits an inhibitory signal to T cells. The protein contains a V domain, a transmembrane domain, and a cytoplasmic tail. Alternate transcriptional splice variants, encoding different isoforms, have been characterized. The membrane-bound isoform functions as a homodimer

interconnected by a disulfide bond, while the soluble isoform functions as a monomer.

Mutations in this gene have been associated with insulin-dependent diabetes mellitus, Graves

disease, Hashimoto thyroiditis, celiac disease, systemic lupus erythematosus, thyroid-associated orbitopathy, and other autoimmune diseases. [provided by RefSeq, Jul 2008]

shRNA Design: These shRNA constructs were designed against multiple splice variants at this gene locus. To

be certain that your variant of interest is targeted, please contact <u>techsupport@origene.com</u>. If you need a special design or shRNA sequence, please utilize our <u>custom shRNA service</u>.







# Performance Guaranteed:

OriGene guarantees that the sequences in the shRNA expression cassettes are verified to correspond to the target gene with 100% identity. One of the four constructs at minimum are guaranteed to produce 70% or more gene expression knock-down provided a minimum transfection efficiency of 80% is achieved. Western Blot data is recommended over qPCR to evaluate the silencing effect of the shRNA constructs 72 hrs post transfection. To properly assess knockdown, the gene expression level from the included scramble control vector must be used in comparison with the target-specific shRNA transfected samples.

For non-conforming shRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the shRNA kit. To arrange for a free replacement with newly designed constructs, please contact Technical Services at techsupport@origene.com. Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled shRNA control (Western Blot data preferred).